MacroGenics Amendment Incorporates Sales Milestone Payment Obligation From Royalty Purchase Agreement And Guaranty Of Such Obligation By Sanofi; Amendment Eliminates Any Obligation For Provention Bio To Pay Royalty Interest To Company
Portfolio Pulse from Benzinga Newsdesk
MacroGenics has amended its royalty purchase agreement, incorporating a sales milestone payment obligation guaranteed by Sanofi. The amendment also eliminates any obligation for Provention Bio to pay royalty interest to MacroGenics, according to an SEC filing.
September 22, 2023 | 8:48 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
MacroGenics has amended its royalty purchase agreement, which could potentially affect its future revenues.
The amendment of the royalty purchase agreement could potentially affect MacroGenics' future revenues, depending on the sales milestones achieved and the absence of royalty interest from Provention Bio. However, the exact impact is uncertain without more specific details.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100
NEUTRAL IMPACT
Sanofi has guaranteed a sales milestone payment obligation as part of MacroGenics' amended royalty purchase agreement.
Sanofi's guarantee of the sales milestone payment obligation could potentially impact its financial obligations, depending on the sales milestones achieved. However, the exact impact is uncertain without more specific details.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70